Target RWE, a clinical evidence generation company, has announced three senior leadership appointments to support its growth. Steve Swanson has been promoted to chief commercial officer, leading commercial strategy and partnerships with biopharma and healthcare companies. Emily Akin joins as head of delivery, overseeing clinical operations and data curation. She previously led Flatiron Trials and Research Network at Flatiron Health. Ashley Pierce has been appointed head of finance, bringing experience from Syneos Health and Capitol Broadcasting Company. The company, backed by investment firm Highlander Health, specialises in real-world evidence generation designed to meet regulatory standards for drug development. The leadership team collectively brings nearly 70 years of experience across life sciences and healthcare to advance Target RWE's evidence generation and clinical trial capabilities.

Target RWE announces upcoming presentations at AASLD - The Liver Meeting 2025. DURHAM, N.C.-(BUSINESS WIRE)-Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced it will have multiple presentations focused on the testing and related outcomes of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting(R) 2025, taking place November 7-11, 2025 in Washington, D.C. Poster Number: 2114 Date and Time: November 8, 2025, 8:00 am - 5:00 pm ET Presentation Title: Changes in the Fibrosis-4 (FIB-4) score accurately reflects the disease trajectory of metabolic dysfunction associated steatotic liver disease. Presenter: Vinay Jahagirdar, MD, GI Fellow, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University Health System, Richmond, Virginia. Summary: A FIB-4 score of 1.3-2.6 reflects an intermediate risk stratum of MASLD where secondary tests with vibration-controlled transient elastography (VCTE) repeat testing is recommended. VCTE is not, however, universally available and the utility of repeat FIB-4 testing to assess changes in clinical status in MASLD is not known. The study authors hypothesized that changes in FIB-4 will coordinately track the risk of clinical outcomes in MASLD. The aim of this study was to define the performance of changes in FIB-4 as a disease-monitoring test in MASLD. The authors concluded that changes in FIB-4 predict future risk of adverse health outcomes independent of age and changes in BMI. Thus, in this intermediate risk FIB-4 category especially with T2DM, repeat testing and change in FIB-4 can be used to assess prognosis and disease trajectory. Poster Number: 2618 Date and Time: November 8, 2025, 8:00 am - 5:00 pm ET Presentation Title: Clinical characteristics and outcomes of patients with presumed MASLD who meet MetALD criteria in the TARGET-NASH cohort Presenter: A. Sidney Barritt IV, MD, MSCR, Professor of Medicine, Director of Hepatology, and Transplant Hepatology Program Director in the Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill. Summary: Many patients with hepatic steatosis are presumed to have MASLD due to comorbid cardiovascular (CV) risk factors. However, alcohol use may not be accurately quantified by providers or fully disclosed by some patients. The characteristics and outcomes of patients with MASLD and increased alcohol intake - metabolic dysfunction and alcohol-related liver disease (MetALD) - are unknown. The study sought to describe these patients in the TARGET-NASH cohort and found that despite younger age and fewer metabolic risk factors, MetALD patients suffered a similar number of incident, major adverse cardiovascular(MACE) events on a faster timeframe compared with traditional MASLD patients. About Target RWE Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy. Visit our website to learn more: https://targetrwe.com/